BioCentury

8:00 AM GMT, Mar 15, 2004
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Whetting pharma's appetite

Early Bird Dealmaking

Whetting pharma's appetite

Though deals for late stage products promise a more timely impact on earnings, the need for innovation remains urgent for pharma licensing specialists, who say they are willing to pay more for earlier technology because the quality of biotech R&D is increasing.

Indeed, Merck & Co. Inc., AstraZeneca plc

Read the full 528 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.